Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated With RAS-associated Autoimmune Leukoproliferative Disease.

Journal of pediatric hematology/oncology - 1 Nov 2018

Toyoda Hidemi, Deguchi Takao, Iwamoto Shotaro, Kihira Kentaro, Hori Hiroki, Komada Yoshihiro, Hirayama Masahiro

Abstract excerpt

Recently, a new disease of lymphocyte homeostasis caused by somatic mosaicism for the RAS mutation has been discovered (known as RALD, RAS-associated leukoproliferative disorder). Since few cases have been reported in literature, the prognosis and standard treatment for autoimmune diseases associated with RALD remain poorly understood. Standard rituximab therapy (375 mg/m for 4 wk) is effective in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Hemolytic
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Purpura, Thrombocytopenic, Idiopathic

Share to Rituximab

Source

Identifiers

PMID: 30080751
DOI: 10.1097/MPH.0000000000001276

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated With RAS-associated Autoimmune Leukoproliferative Disease.PMID 30080751Read ↗

Summary and Analysis of 13 RAS-Associated Autoimmune Leukoproliferative Disease Clinical FeaturesSemantic proximity Read ↗

[Ras-associated autoimmune leukoproliferative disorder: a report of 2 cases and literature review].Semantic proximity Read ↗

Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).Semantic proximity Read ↗

Ras‐associated autoimmune lymphoproliferative disorderSemantic proximity Read ↗

RAS-associated Autoimmune Leukoproliferative Disease (RALD-KRAS) Consistent with the Clinical Diagnosis of Rosai-Dorfman Disease: A 15-year Follow-up.Semantic proximity Read ↗

JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.Semantic proximity Read ↗

Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD).Semantic proximity Read ↗

Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD).Semantic proximity Read ↗

Sirolimus is effective in autoimmune lymphoproliferative syndrome-type III: A pedigree case report with homozygous variation PRKCD.Semantic proximity Read ↗

Distinct αβ double-negative T cells discriminate between autoimmune lymphoproliferative syndrome and RAS-associated lymphoproliferative diseaseSemantic proximity Read ↗

Natural history of Ras-associated autoimmune leukoproliferative disorder: A 20-year follow-up of a NRAS-mutated patient excluding a malignant progression.Semantic proximity Read ↗

The expanding spectrum of the autoimmune lymphoproliferative syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.